AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-9 (cancelled)

Claim 10 (previously presented): An implant for controlled, sustained drug release comprising:

a pharmacologically acceptable biodegradable polymer which is degraded at the site of implantation, wherein said biodegradable polymer comprises at least about 20 weight percent of the implant;

a first therapeutically active agent at a concentration from 10 to 50 weight percent of the implant;

a release modulator comprising hydroxypropylmethylcellulose at a concentration from 10 to 50 weight percent of the implant;

wherein said ipmlant is an anhydrous solid structure which is degraded at the site of implantation and releases said first therapeutically active agent within a therapeutic dosage which does not vary by more than about 100% for a period of at least about 3 days after implantation.

Claims 11-12 (cancelled)

Claim 13 (previously presented): An implant according to claim 10, wherein said anhydrous solid structure is a particle, sheet, patch, plaque, fiber, microcapsule, microsphere or disc.

Claim 14 (cancelled)

Claim 15 (previously presented): An implant according to claim 10, wherein said release modulator further comprises a second therapeutically active agent.

Claim 16 (previously presented): An implant according to claim 15, wherein said first therapeutically active agent is a steroid and said second therapeutically active agent is a water soluble antibiotic.

Claim 17 (previously presented): An implant according to claim 15, wherein said first therapeutically active agent is a non-steroidal antiinflammatory drug and said second therapeutically active is a water soluble antibiotic.

Claim 18 (previously presented): An implant according to claim 10, wherein said biodegradable polymer is poly-lactate glycolate acid copolymer.

Claim 19 (previously presented): An implant for controlled, sustained drug release comprising:

poly-lactate glycolic acid copolymer at a concentration of at least about 20 weight percent of the implant;

a therapeutically active antiinflammatory drug at a concentration from 10 to 50 weight percent of the implant;

a release modulator comprising hydroxypropylmethylcellulose at a concentration from 10 to 50 weight percent of the implant;

wherein said implant is an anhydrous solid structure which releases said therapeutically active antiinflammatory within a therapeutic dosage that does not vary by more than about 100% for a period of at least about 3 days.

Claim 20 (previously presented): An implant for controlled, sustained drug release comprising:

poly-lactate glycolic acid copolymer at a concentration of at least about 20 weight percent of the implant;

a therapeutically active steroid at a concentration from 10 to 50 weight percent of the implant;

a release modulator comprising hydroxypropylmethylcellulose at a concentration from 10 to 50 weight percent of the implant;

wherein said implant is an anhydrous solid structure which is degraded at the site of implantation and releases said therapeutically active steroid within a therapeutic dosage which does not vary by more than about 100% for a period of at least about 3 days after implantation.

Claim 21 (cancelled)

Claim 22 (previously presented): An implant according to claim 20, wherein said anhydrous solid structure is a particle, sheet, patch, plaque, fiber, microcapsule, microsphere or disc.

Claim 23 (previously presented): An implant according to claim 20, wherein said release modulator further comprises a second therapeutically active agent.

Claim 24 (previously presented): An implant according to claim 23, wherein said second therapeutically active agent is a water soluble antibiotic.

Claim 25 (previously presented): An implant for controlled, sustained drug release comprising:

poly-lactate glycolic acid copolymer at a concentration of at least about 20 weight percent of the implant;

a therapeutically active non-steroidal antiinflammatory drug at a concentration from 10 to 50 weight percent of the implant;

a release modulator comprising hydroxypropylmethylcellulose at a concentration from 10 to 50 weight percent of the implant;

wherein said implant is an anhydrous solid structre which releases said therapeutically active non-steroidal antiinflammatory drug within a therapeutic dosage which does not vary by more than about 100% for a period of at least about 3 days after implantation.

Claim 26-27 (cancelled)

Claim 28 (previously presented): An implant according to claim 25, wherein said release modulator further comprises a second therapeutically active agent.

Claim 29 (previously presented): An implant according to claim 28, wherein said second therapeutically active agent is a water soluble antibiotic.

Claims 30-33 (cancelled)

Claim 34 (currently amended): An implant for drug release comprising:

a pharmacologically acceptable biodegradable polymer, wherein said biodegradable polymer is at least about 10 weight percent of the implant;

a first therapeutically active agent at a concentration from 1 to 80 weight percent of the implant;

a release modulator at a concentration from 10 to 50 weight percent of the implant;

wherein said implant is an anhydrous solid structure which is degraded at a site of implantation within ~~the~~ an ocular region.

Claim 35 (previously presented): An implant according to claim 34 wherein the site of implantation within the ocular region is selected from the group consisting of the anterior chamber, the posterior chamber, the vitreous cavity, the suprachoroidal space, the subconjunctiva, the episcleral, the intracorneal, the epicorneal, the sclera, and the pars plana.

Claim 36 (previously presented): An implant according to claim 34, wherein the anhydrous solid structure is a sheet, fiber, or microsphere.

Claim 37 (previously presented): An implant according to claim 34, wherein the biodegradable polymer is a copolymer of glycolic and lactic acid.

Claim 38 (previously presented): An implant according to claim 34 wherein the first therapeutically active agent is a steroid.

Claim 39 (previously presented): An implant for drug release comprising:

a pharmacologically acceptable biodegradable polymer, wherein said biodegradable polymer is at least about 10 weight percent of the implant;

a first therapeutically active agent at a concentration from 1 to 80 weight percent of the implant;

a release modulator at a concentration from 10 to 50 weight percent of the implant;

wherein said implant is an anhydrous solid structure sized for implantation within the ocular region and is degraded at a site of implantation.

Claim 40 (previously presented): An implant according to claim 39 wherein the anhydrous solid structure is a sheet, fiber, or microsphere.

Claim 41 (previously presented): An implant according to claim 39 wherein the anhydrous solid structure is a sheet, the sheet having dimensions in the range of about 3-10 mm x 5-10 mm and a thickness of about 0.1 to about 1.0 mm.

Claim 42 (previously presented): An implant according to claim 39 wherein the anhydrous solid structure is a fiber, the fiber having a diameter in the range of about 0.05 to about 3 mm and a length in the range of about 0.5 to about 10 mm.

Claim 43 (currently amended): An implant according to claim 39 wherein the anhydrous solid structure is a microsphere, the microsphere having a diameter in the range of about 2μm to about ~~4μm~~ 3mm.